Skip to main content

Advertisement

SpringerLink
Log in

Astragaloside IV for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis

  • Evidence-Based Integrative Medicine
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To explore the cardioprotective effects of astragaloside IV (AS-IV) in heart failure (HF).

Methods

PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, Chinese Bio-medical Literature and Retrieval System (SinoMed), China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched from inception to November 1, 2021 for animal experiments to explore AS-IV in treating HF in rats or mice. The left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), left ventricular weight-to-body weight (LVW/BW) and B-type brain natriuretic peptide (BNP) were recorded. The qualities of included studies were assessed by the risk of bias according to the Cochrane handbook. Meta-analysis was performed using Stata 13.0.

Results

Twenty-one articles involving 558 animals were considered. Compared with the control group, AS-IV improved cardiac function, specifically by increasing LVEF (mean difference (MD)=6.97, 95% confidence interval (CI)=5.92 to 8.03, P<0.05; fixed effects model) and LVFS (MD=7.01, 95% CI=5.84 to 8.81, P<0.05; fixed effects model), and decreasing LVEDD (MD=−4.24, 95% CI=−4.74 to −3.76, P<0.05; random effects model) and LVESD (MD=−4.18, 95% CI=−5.26 to −3.10, P<0.05; fixed effects model). In addition, the BNP and LVW/BW levels were decreased in the AS-IV treatment group (MD=−9.18, 95% CI=−14.13 to −4.22, P<0.05; random effects model; MD=−1.91, 95% CI=−2.42 to −1.39, P<0.05; random effects model).

Conclusions

AS-IV is a promising therapeutic agent for HF. However, this conclusion needs to be clinically validated in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Availability of Data and Materials

The original contributions presented in the study are included in the article/supplementary materials, further inquiries can be directed to the corresponding author/s.

References

  1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726.

    Article  CAS  PubMed  Google Scholar 

  2. Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet 2019;393:1034–1044.

    Article  CAS  PubMed  Google Scholar 

  3. Zang Y, Wan J, Zhang Z, Huang S, Liu X, Zhang W. An updated role of astragaloside IV in heart failure. Biomed Pharmacother 2020;126:110012.

    Article  CAS  PubMed  Google Scholar 

  4. Wang Z, Zhu Y, Zhang Y, Zhang J, Ji T, Li W, et al. Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM. Biomed Pharmacother 2020;127:110081.

    Article  CAS  PubMed  Google Scholar 

  5. Sui YB, Zhang KK, Ren YK, Liu L, Liu Y. The role of Nrf2 in astragaloside IV-mediated antioxidative protection on heart failure. Pharm Biol 2020;58:1192–1198.

    Article  PubMed  Google Scholar 

  6. Sui YB, Wang Y, Liu L, Liu F, Zhang YQ. Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway. Pharm Biol 2019;57:48–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Dai H, Jia G, Lu M, Liang C, Wang Y, Wang H. Astragaloside IV inhibits isoprenaline-induced cardiac fibrosis by targeting the reactive oxygen species/mitogen-activated protein kinase signaling axis. Mol Med Rep 2017;15:1765–1770.

    Article  CAS  PubMed  Google Scholar 

  8. Tang B, Zhang JG, Tan HY, Wei XQ. Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure. Biosci Rep 2018;38:BSR20171036.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Chen C, Lin Q, Zhu XY, Xia J, Mao T, Chi T, et al. Pre-clinical evidence: berberine as a promising cardioprotective candidate for myocardial ischemia/reperfusion injury, a systematic review, and meta-analysis. Front Cardiovasc Med 2021;8:646306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–1558.

    Article  PubMed  Google Scholar 

  12. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 2010;1:97–111.

    Article  PubMed  Google Scholar 

  13. Tang B, Zhang JG, Tan HY, Wei XQ. Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure. Biosci Reports 2018;38:BSR20171036.

    Article  CAS  Google Scholar 

  14. Dong ZW, Zhao P, Xu M, Zhang C, Guo W, Chen HH, et al. Astragaloside IV alleviates heart failure via activating PPAR alpha to switch glycolysis to fatty acid beta-oxidation. Scientific Reports 2017;77:2691.

    Article  Google Scholar 

  15. Ji Y, Wang T, Zhang X, Li L, Li L, Guo Y, et al. Astragalosides increase the cardiac diastolic function and regulate the “Calcium sensing receptor-protein kinase C-protein phosphatase 1” pathway in rats with heart failure. Biomed Pharmacother 2018;103:838–843.

    Article  CAS  PubMed  Google Scholar 

  16. Liu J, Li Y, Bian X, Xue N, Yu J, Dai S, et al. Astragaloside IV alleviates heart failure by regulating SUMO-specific protease 1. Oxid Med Cell Longev 2021;22:1076.

    CAS  Google Scholar 

  17. Nie P, Meng F, Zhang J. Astragaloside IV exerts a myocardial protective effect against cardiac hypertrophy in rats, partially via activating the Nrf2/HO-1 signaling pathway. Oxid Med Cell Longev 2019;2019:4625912.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Sui YB, Wang Y, Liu L, Li F, Zhang YQ. Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway. Pharm Biol 2019;57:48–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wang QN, Yang XF, Song Y, Sun XW, Li WT, Zhang L, et al. Astragaloside IV-targeting miRNA-1 attenuates lipopolysaccharide-induced cardiac dysfunction in rats through inhibition of apoptosis and autophagy. Life Sci 2021;275:119414.

    Article  CAS  PubMed  Google Scholar 

  20. Sui YB, Zhang KK, Ren YK, Liu L, Liu Y. The role of Nrf2 in astragaloside IV-mediated antioxidative protection on heart failure. Pharm Biol 2020;58:1192–1198.

    Article  PubMed  Google Scholar 

  21. Zhao Z, Wang W, Wang F, Zhao K, Han Y, Xu W, et al. Effects of astragaloside IV on heart failure in rats. Chin Med 2009;4:4–6.

    Article  Google Scholar 

  22. Chen Q, Ji X, Kan D, Han X, Wang Y, Yu W, et al. The effect of astragaloside IV on cardiac function in rats with internal stop of compound water drink. Chin J Exp Tradit Med Formul (Chin) 2017;23:100–105.

    Google Scholar 

  23. Jiang H, Zhang J, Tan H, Wei X. Effects of astragaloside IV on myocardial fibrosis and expression of connective tissue growth factor in rats with chronic heart failure. Chin Circ J (Chin) 2016;31:165–169.

    Google Scholar 

  24. Li CS, Dai HL, Yang XY, Guo H, Duan H, Xiao M. Experimental study on the effect of astragaloside IV on cardiomyocyte apoptosis and expression of P-Cx43 in heart failure model rats. J Clin Exp Med (Chin) 2018;17:1233–1237.

    Google Scholar 

  25. Lv Q. Effects of astragaloside IV on myocardium of rats with heart failure. J North Pharm (Chin) 2018;15:156–158.

    Google Scholar 

  26. Song AX, Wang L, Zhang YY. Effects of astragaloside IV on cardiomyocyte apoptosis in rats with chronic heart failure through TGF-β1/Smad3 signaling pathway and its mechanism. Chin J Integr Med Cardio-Cerebrovasc Dis (Chin) 2021;19:1645–1651.

    Google Scholar 

  27. Song BC, Meng FJ, Nie P, Wei XQ, Zhang JG. Effects of astragaloside IV on heart failure in rats by regulating nuclear factor E2-related factor 2/heme oxygenase-1 signaling pathway. Chin J Geriatrics (Chin) 2020;39:1072–1076.

    Google Scholar 

  28. Tang B, Zhang JG, Tan HY, Wei XQ. Protective effect of astragaloside IV on heart in rats with chronic heart failure. Shanghai J Tradit Chin Med (Chin) 2016;50:89–94.

    Google Scholar 

  29. Tang B, Zhang JG, Tan HY, Wei XQ. Effects of astragaloside IV on myocardial fibrosis and energy metabolism in rats with chronic heart failure. Chin J Pathophysiol (Chin) 2017;33:411–416.

    Google Scholar 

  30. Wang SF, Chen YS, Wang N, Du LX, Li ZL, Li TT. Experimental study on the effects of astragaloside IV on serum inflammatory factors and myocardial remodeling in rats with heart failure. World J Integr Tradit West Med (Chin) 2020;15:1661–1665.

    Google Scholar 

  31. Wei L, Wang LJ, He JQ, Zhang L, Wang JY, Fang HC, et al. Protective effect of astragaloside IV on myocardial fibrosis in mice with heart failure based on AKT/GSK3-β/SNAIL pathway. Tradit Chin Drug Res Clin Pharmacol (Chin) 2021;32:1231–1237.

    CAS  Google Scholar 

  32. Zhang M, Quan YH, Guo MX, Gan PP, Liu C, Huang F. Effects of astragaloside IV on ventricular remodeling and myocardial energy metabolism in a rat model of adriamycin-induced heart failure. Chin J Gerontol (Chin) 2021;41:1494–1497.

    CAS  Google Scholar 

  33. Zhao Y, Yang D, Yu SS. Effects of astragaloside IV on myocardial cell apoptosis and P-Cx43 expression in rats with chronic heart failure. J Clin Exp Med (Chin) 2018;17:2143–2147.

    Google Scholar 

  34. Shi H, Zhou P, Gao G, Liu PP, Wang SS, Song R, et al. Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway. J Food Biochem 2021;45:e13757.

    Article  CAS  PubMed  Google Scholar 

  35. Wang Q, Yang X, Song Y, Sun X, Li W, Zhang L, et al. Astragaloside IV-targeting miRNA-1 attenuates lipopolysaccharide-induced cardiac dysfunction in rats through inhibition of apoptosis and autophagy. Life Sci 2021;275:119414.

    Article  CAS  PubMed  Google Scholar 

  36. Yin B, Hou XW, Lu ML. Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways. Acta Pharmacol Sin 2019;40:599–607.

    Article  CAS  PubMed  Google Scholar 

  37. Dong Z, Zhao P, Xu M, Zhang C, Guo W, Chen H, et al. Astragaloside IV alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation. Sci Rep 2017;7:2691.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Liu ZH, Liu HB, Wang J. Astragaloside IV protects against the pathological cardiac hypertrophy in mice. Biomed Pharmacother 2018;97:1468–1478.

    Article  CAS  PubMed  Google Scholar 

  39. Liu J, Li Y, Bian X, Xue N, Yu J, Dai S, et al. Astragaloside IV alleviates heart failure by regulating SUMO-specific protease 1. Exp Ther Med 2021;22:1076.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Jia G, Leng B, Wang H, Dai H. Inhibition of cardiotrophin-1 overexpression is involved in the anti-fibrotic effect of astrogaloside IV. Mol Med Rep 2017;16:8365–8370.

    Article  CAS  PubMed  Google Scholar 

  41. Wang Z, Zhu Y, Zhang Y, Zhang J, Ji T, Li W, et al. Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM. Biomed Pharmacother 2020;127:110081.

    Article  CAS  PubMed  Google Scholar 

  42. Zhao Y, Liu Z, Zhang H. Astragaloside protects myocardial cells from apoptosis through suppression of the TLR4/NF-κB signaling pathway. Exp Ther Med 2018;15:1505–1509.

    CAS  PubMed  Google Scholar 

  43. Wang Z, Wu Y, Pei C, Wang M, Wang X, Shi S, et al. Astragaloside IV pre-treatment attenuates PM2.5-induced lung injury in rats: Impact on autophagy, apoptosis and inflammation. Phytomedicine 2022;96:153912.

    Article  CAS  PubMed  Google Scholar 

  44. Zhang X, Qu H, Yang T, Liu Q, Zhou H. Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway. Cell Cycle 2022;21:2309–2322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China

    Xing-xing Li, Dong Li, Xiao-yun Cui, Kun Zhou, Jing Liu, Jin-jin Lu, Yang Wu & Yan Li

  2. Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China

    Qian Lin

Authors
  1. Xing-xing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-yun Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jin-jin Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qian Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Li XX and Li Y designed the study. Li XX drafted the manuscript. Wu Y and Lin Q guided and supervised the implementation of the whole study. Li D, Cui XY and Zhou K conducted data sorting and statistical analysis. Liu J and Lu JJ participated in graphic drawing. Li Y revised the manuscript and obtained financial support.

Corresponding author

Correspondence to Yan Li.

Additional information

Conflict of Interest

The authors declare no competing financial interests.

Supported by National Natural Science Foundation of China (No. 81973622) and Capital’s Funds for Health Improvement and Research (No. 2020-2-4201)

Electronic Supplementary Material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Xx., Li, D., Cui, Xy. et al. Astragaloside IV for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis. Chin. J. Integr. Med. 29, 626–633 (2023). https://doi.org/10.1007/s11655-023-3636-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-023-3636-x

Keywords

Search

Navigation